Previous 10 | Next 10 |
Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will exercise its option to purchase all rights to a G-coupled protein receptor (GPCR) library and its propriet...
AcornMed Biotechnology Co., Ltd. (AcornMed), a precision medicine organization that specializes in the testing and analysis of solid and blood tumors, announced today that they will incorporate Twist Bioscience next generation sequencing (NGS) target enrichment and library preparation p...
Twist Bioscience ([[TWST]] +0.2%) has signed an agreement enabling multiple academic laboratories at Stanford University to access the company's innovative antibody discovery and optimization services as well as its unique library for biologics discovery.Twist will receive technology access f...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience’s ...
Twist Bioscience (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, is proud to be Certified™ by Great Place to Work®. The prestigious award is based entirely on what current employees say ab...
Let's face it, we all wish we could have bought and held a stock that ended up rising 50 or 100 times in value over the last decade. Unfortunately, capturing that type of gain typically means investing while the company is still small and its outcome is uncertain. Trillium Therapeutic...
Twist Bioscience ([[TWST]] -0.4%) has signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, a subsidiary of Kyowa Kirin ([[KYKOF]]) to discover novel antibodies for therapeutic use against an undisclosed G protein-coupled receptor ((GPCR)) target molecule.Under the ter...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyow...
Twist Bioscience Corporation ([[TWST]] -7.8%) announced that the FDA has granted the emergency use authorization for its SARS-CoV-2 next-generation sequencing (“NGS”) assay.The capture-based in vitro diagnostic test uses SARS-CoV-2 synthetic RNA controls from Twist Bio...
- Ability to sequence and surveil evolution of virus mutations over time and geography - - Enables batch analysis of up to 96 samples at once; higher-plex assay development ongoing - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...